Effectiveness and safety of repeated quadruple therapy in Helicobacter pylori infection after failure of second-line quadruple therapy: Repeated quadruple therapy as a third-line therapy Lee et al. Retrial of 2nd-line bismuth quadruple therapy

Helicobacter

Volumn 16, Issue 5, 2011, Pages 410-414

  Lee, Sang Kyu ^a   Lee, Sang Woo ^a   Park, Jae Yeon ^a   Kwon, Bo Sung ^a   Kim, Seung Young ^a   Hyun, Jong Jin ^a   Kim, Jeong Han ^a   Jung, Sung Woo ^a   Koo, Ja Seol ^a   Yim, Hyung Joon ^a   Choi, Jai Hyun ^a  

^a Korea University College of Medicine   (South Korea)

Author keywords

Bismuth; Quadruple therapy; Re treatment; Second line therapy

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CLARITHROMYCIN; ESOMEPRAZOLE; METRONIDAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; TETRACYCLINE;

ABDOMINAL DISCOMFORT; ADULT; ANOREXIA; ARTICLE; BITTER TASTE; CLINICAL ARTICLE; CONSTIPATION; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; ERADICATION THERAPY; ERYTHEMA; FATIGUE; FEMALE; GASTROINTESTINAL ENDOSCOPY; HEADACHE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; INSOMNIA; KOREA; MALE; NAUSEA; PRIORITY JOURNAL; PRURITUS; RETREATMENT; SIDE EFFECT; SWEATING; UREA BREATH TEST; VOMITING; WEAKNESS;

ADULT; ANTI-BACTERIAL AGENTS; BISMUTH; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; KOREA; MALE; METRONIDAZOLE; MIDDLE AGED; PATIENT COMPLIANCE; PROTON PUMP INHIBITORS; TETRACYCLINE; TREATMENT OUTCOME;

HELICOBACTER PYLORI;

EID: 80052987111     PISSN: 10834389     EISSN: 15235378     Source Type: Journal    
DOI: 10.1111/j.1523-5378.2011.00870.x     Document Type: Article

References (28)

1. Di Mario F, Cavallaro LG, Scarpignato C. 'Rescue' therapies for the management of Helicobacter pylori infection. Dig Dis 2006;24:113-30.
2. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, Hunt R, Rokkas T, Vakil N, Kuipers EJ. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-81.
3. Vakil N, Megraud F. Eradication therapy for Helicobacter pylori. Gastroenterology 2007;133:985-1001.
4. Gisbert JP, Gisbert JL, Marcos S, Pajares JM. Empirical Helicobacter pylori"rescue" therapy after failure of two eradication treatments. Dig Liver Dis 2004;36:7-12.
5. Cianci R, Montalto M, Pandolfi F, Gasbarrini GB, Cammarota G. Third-line rescue therapy for Helicobacter pylori infection. World J Gastroenterol 2006;12:2313-9.
6. Gisbert JP, Pajares JM. Review article: C-urea breath test in the diagnosis of Helicobacter pylori infection - a critical review. Aliment Pharmacol Ther 2004;20:1001-17.
7. Gisbert JP. Second-line rescue therapy of Helicobacter pylori infection. Therap Adv Gastroenterol 2009;2:331-56.
8. Malfertheiner P, Megraud F, O'Morain C, Hungin AP, Jones R, Axon A, Graham DY, Tytgot G; European Helicobacter Pylori Study Group (EHPSG). Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167-80.
9. Gisbert JP, Pajares JM. Review article: Helicobacter pylori"rescue" regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 2002;16:1047-57.
10. Strom M, Sorberg M, Jonsson KA. Immediate repeat course of amoxycillin, metronidazole and omeprazole to eradicate Helicobacter pylori. Aliment Pharmacol Ther 1997;11:311-6.
11. Huang JQ, Hunt RH. Treatment after failure: the problem of "non-responders". Gut 1999;45(Suppl. 1):I40-4.
12. Graham DY. Therapy of Helicobacter pylori: current status and issues. Gastroenterology 2000;118(2 Suppl. 1):S2-8.
13. Megraud F. Basis for the management of drug-resistant Helicobacter pylori infection. Drugs 2004;64:1893-904.
14. de Boer W, Driessen W, Jansz A, Tytgat G. Effect of acid suppression on efficacy of treatment for Helicobacter pylori infection. Lancet 1995;345:817-20.
15. Goddard AF, Jessa MJ, Barrett DA, Shaw PN, Idstrom JP, Cederberg C, Spiller RC. Effect of omeprazole on the distribution of metronidazole, amoxicillin, and clarithromycin in human gastric juice. Gastroenterology 1996;111:358-67.
16. Graham DY, Hoffman J, el-Zimaity HM, Graham DP, Osato M. Twice a day quadruple therapy (bismuth subsalicylate, tetracycline, metronidazole plus lansoprazole) for treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 1997;11:935-8.
17. Graham DY, Osato MS, Hoffman J, Opekun AR, Anderson SY, Kwon DH, El-Zimarty HM. Metronidazole containing quadruple therapy for infection with metronidazole resistant Helicobacter pylori: a prospective study. Aliment Pharmacol Ther 2000;14:745-50.
18. Dore MP, Graham DY, Mele R, Marras L, Nieddu S, Manca A, Realdi G Colloidal bismuth subcitrate-based twice-a-day quadruple therapy as primary or salvage therapy for Helicobacter pylori infection. Am J Gastroenterol 2002;97:857-60.
19. van der Wouden EJ, Thijs JC, van Zwet AA, Sluiter WJ, Kleibeuker JH. The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis. Am J Gastroenterol 1999;94:1751-9.
20. Moshkowitz M, Konikoff FM, Peled Y, Santo M, Hallak A, Bujanover Y, Tiomnq E, Gilat T. High Helicobacter pylori numbers are associated with low eradication rate after triple therapy. Gut 1995;36:845-7.
21. Zullo A, De Francesco V, Manes G, Scaccianoce G, Cristofari F, Hassan C. Second-line and rescue therapies for Helicobacter pylori eradication in clinical practice. J Gastrointestin Liver Dis 2010;19:131-4.
22. Kim N, Kim JM, Kim CH, Park YS, Lee DH, Kim JS, Jung HC, Song IS. Institutional difference of antibiotic resistance of Helicobacter pylori strains in Korea. J Clin Gastroenterol 2006;40:683-7.
23. Lee JH, Hong SP, Kwon CI, et al. The efficacy of levofloxacin based triple therapy for Helicobacter pylori eradication. Korean J Gastroenterol 2006;48:19-24.
24. Carothers JJ, Bruce MG, Hennessy TW, Bensler M, Morris JM, Reasonover AL, Hurlburnt DA, Parkinson AJ, Coleman JM, McMahon BJ. The relationship between previous fluoroquinolone use and levofloxacin resistance in Helicobacter pylori infection. Clin Infect Dis 2007;44:e5-8.
25. Cattoir V, Nectoux J, Lascols C, Deforges L, Delchier JC, Megraud F, Soussy CJ, Cambau E. Update on fluoroquinolone resistance in Helicobacter pylori: new mutations leading to resistance and first description of a gyrA polymorphism associated with hypersusceptibility. Int J Antimicrob Agents 2007;29:389-96.
26. Glocker E, Stueger HP, Kist M. Quinolone resistance in Helicobacter pylori isolates in Germany. Antimicrob Agents Chemother 2007;51:346-9.
27. Perna F, Zullo A, Ricci C, Hassan C, Morini S, Vaira D. Levofloxacin-based triple therapy for Helicobacter pylori re-treatment: role of bacterial resistance. Dig Liver Dis 2007;39:1001-5.
28. Zullo A, Perna F, Hassan C, Ricci C, Saracino I, Morini S, Vaira D. Primary antibiotic resistance in Helicobacter pylori strains isolated in northern and central Italy. Aliment Pharmacol Ther 2007;25:1429-34.